SHILPA MEDICARE LTD. - 530549 - Outcome Of Board Meeting
With reference to the subject cited above, this is to intimate that the Board of Directors in its meeting held on 14 February 2023 which commenced at 02.00 p.m. and concluded at 04: 03 p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 31 December 2022. A copy of Limited Review Report is also enclosed as Annexure 1. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q3 FY23 Conference Call to be held on Wednesday, February 15, 2023 at 04:00 PM IST.
MSCI review: Delhivery added, Shilpa Medicare deleted from smallcap index
All changes will be implemented as of the close of February 28, 2023 SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting To Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St December, 2022
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve The Meeting of Board of Directors of the Company will be held on Tuesday, 14th February, 2023 to inter alia Consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 31st December, 2022 SHILPA MEDICARE LTD. - 530549 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on January 19, 2023 for Dharmavati Bhutada & Others SHILPA MEDICARE LTD. - 530549 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on January 18, 2023 for Dharmavati Bhutada & Others SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 19, 2023 for Dharmavati Bhutada & Others SHILPA MEDICARE LTD. - 530549 - Submission In Compliance With Regulation 76 Of The Securities And Exchange Board Of India (Depositories And Participants) Regulations, 2018 For Quarter Ended 31 December, 2022.
Pursuant to Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find herewith enclosed the Reconciliation of Share Capital Audit Report for Equity Shares dated 18 January 2023 for the Quarter ended 31 December 2022, issued by CS D.S. Rao, Practicing Company Secretary, Hyderabad. SHILPA MEDICARE LTD. - 530549 - Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015.
Submission of Disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 31 December, 2022.